CompletedPhase 1NCT02418793
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OPKO Health, Inc.
- Principal Investigator
- Guy Ben-BashatOPKO Health, Inc.
- Intervention
- MOD-5014(drug)
- Enrollment
- 27 enrolled
- Eligibility
- 18-65 years · MALE
- Timeline
- 2015 – 2018
Study locations (11)
- City of Hope, Duarte, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Bleeding & Clotting Disorders Institute, Peoria, Illinois, United States
- Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States
- Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
- UPMC Presbyterian Shadyside, Pittsburgh, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- The Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02418793 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China